Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabazitaxel + abiraterone acetate
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Cabazitaxel + abiraterone acetate is a combination therapy used primarily in the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly in patients previously treated with docetaxel. Cabazitaxel is a second-generation, semisynthetic taxane that acts as a microtubule inhibitor, promoting microtubule polymerization and inhibiting cell division, leading to tumor cell death. Abiraterone acetate is an androgen biosynthesis inhibitor that blocks Cytochrome P450 17A1, reducing androgen production and thereby suppressing tumor growth driven by androgens. The combination leverages both cytotoxic (cabazitaxel) and hormone-directed (abiraterone) mechanisms to improve progression-free survival (PFS), PSA response rates, and delay time to progression compared to monotherapy regimens[2][4][5][6].
- Other names
- cabazitaxel + abiraterone acetate
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cabazitaxel + abiraterone acetate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabazitaxel + abiraterone acetate.